Xenetic Biosciences, Inc.

Xenetic partner doses first patient in DNase CAR T-cell study
Investing.com · 15 Oct 2026
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
Corsicana Daily Sun · 15 Oct 2026
Xenetic Biosciences, Inc. (XBIO) Stock Price Prediction for 2026, 2030-2040
Traders Union · 12 Oct 2026
Xenetic Biosciences (XBIO) Ticks Higher to $2.24 as Shares Hold Above Key Support - Dividend Stock Picks
https://www.siam.in/ · 05 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.